The Role of the Human Microbiome in Patients After Pancreatic Resection.

Pancreas Cancer Clinical Trial

— MiPac  

Official title:

Establishing the Role of the Human Microbiome in Patients With a Presumed Pancreatic or Periampullary (Pre)Malignancy and Pancreatic Resection.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06381882
• Other study ID #: MiPac
• Status: Not yet recruiting
• Start date: May 1, 2024
• Est. completion date: November 1, 2026

Study information

• Verified date: April 2024
• Source: St. Antonius Hospital
• Contact: Robert Verdonk, dr.
• Phone: +088 320 56 00
• Email: r.verdonk[@]antoniusziekenhuis.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to classify patients that undergo pancreatic resection for presumed pancreatic or periampullary malignancy into high and low risk groups for postoperative complications based on longitudinal saliva, rectal/faecal, tumor, blood and/or bile microbiome profiles. To identify the dynamics of the microbiome, as well as the possibly related short-term and long-term complications, multiple samples at different timepoints are needed from the patients.

Description:

Rationale: Resection is the only potentially curative option for pancreatic and periampullary cancer, a complex procedure with a high risk of complications of 30% to 73%. Research shows the presence of altered bacterial populations within fecal, pancreatic fluid, bile and jejunal samples of patients after pancreatic resection compared to healthy samples. Moreover, specific gut microbial composition in the pre- and postoperative period were associated with a higher risk of developing complications after pancreatic resection in small studies. Further research on a larger scale is necessary to validate these findings and to evaluate targeted microbiome modifications to improve outcomes in patients after pancreatic resection. Objective: The primary objective of this study is to classify patients that undergo pancreatic resection for presumed pancreatic or periampullary malignancy into high and low risk groups for postoperative complications based on longitudinal microbiome profiles. Study design: Prospective observational cohort study. Study population: 200 adult patients with resectable pancreatic or periampullary presumed (pre)malignancy. Main study parameters/endpoints: The primary endpoint is a composite of postoperative complications including pancreatic fistula, bleeding, gastroenterostomy-, bile- or chyle leakage, delayed gastric emptying, cholangitis, sepsis and organ failure. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All participants will be offered the standard of care. In addition, rectal swabs, faeces, salivary, bile, blood and tumor samples will be collected at different time points perioperatively. Participating in this study carries no additional risks.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: November 1, 2026
• Est. primary completion date: May 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patient with a resectable, borderline resectable or locally advanced pancreatic and periampullary presumed (pre)malignancy.
• The intention of the treatment must be curative including surgery and (neo-)adjuvant chemotherapy.
• Willing and able to adhere to the study procedures described in this protocol and to grant the study team access to the electronic patient file and other data that are required to answer the research questions described in this protocol.

Exclusion Criteria:

• Inability to provide adequate informed consent (e.g. language barrier, illiteracy)

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Microbial Colonization
• Pancreas Adenocarcinoma
• Pancreas Cancer
• Pancreas Neoplasm
• Pancreatic Neoplasms
• Periampullary Cancer
• Periampullary Carcinoma

Intervention

Procedure:
• Pancreatic resection
Any kind of pancreatic resection will be included

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
St. Antonius Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Risk stratification postoperative complications	The primary objective of this study is to classify patients that undergo pancreatic resection into high and low risk groups for postoperative complications, based on saliva, blood, tumor, bile and/or rectal/faecal microbiome profiles.	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Long time oncological outcomes - site of recurrence	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and long term oncological outcomes (e.g. site of recurrence).	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Long time oncological outcomes - disease free survival	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and long term oncological outcomes (e.g. disease free survival).	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Long time oncological outcomes - overall survival	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and long term oncological outcomes (e.g. overall survival).	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Complications neoadjuvant chemotherapy	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and complications of neoadjuvant chemotherapy.	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Complications adjuvant chemotherapy	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and complications of adjuvant chemotherapy.	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Response to neoadjuvant chemotherapy	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and response to neoadjuvant chemotherapy as judged by computed tomography (CT) scan and histological respons.	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Complications bile duct drainage	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and complications associated with bile duct drainage.	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Postoperative endocrine insufficiency	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and postoperative endocrine insufficiency (defined as need for new pharmacologic intervention).	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge
Secondary	Postoperative exocrine insufficiency	Secondary objectives include, but are not limited to, finding associations between microbiome profiles and postoperative exocrine insufficiency (defined as need for new pharmacologic intervention).	- (Before start chemotherapy), peroperative, preoperative, postoperative day 1/3, +/- 2 weeks post-discharge